At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Ponatinib Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Ponatinib Hydrochloride, and 1 other intervention for Malignant Hepatobiliary Neoplasm. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This pilot phase II trial studies how well ponatinib hydrochloride works in treating patients with biliary cancer that has spread to other places in the body and that have alterations (fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Hepatobiliary Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartDec 2014
Primary CompletionMay 2018
Study CompletionJun 2019
TodayJul 2026
First PostedOct 15, 2014
Enrollment StartDec 1, 2014
Primary CompletionMay 1, 2018
Study CompletionJun 14, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.7 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Ponatinib Hydrochloridedrug
Given PO
Quality-of-Life Assessmentother
Ancillary studies